文献速递儿童感染儿童血液肿瘤与免疫

儿童化疗和(或)造血干细胞移植后乙肝疫苗再接种的有效性与安全性

[Efficacy and safety of hepatitis B re-vaccination in children after completion of chemotherapy and(or) hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2020-01-01

该前瞻性研究纳入239例完成化疗和(或)HSCT的患儿,发现治疗前HBsAb阳性的179例中133例(74.3%)治疗后转阴;48例HBsAb阴性患儿再接种3剂乙肝疫苗后47例(97.9%)转阳,无严重不良反应。HSCT和治疗前HBsAb低于328.2 U/L是转阴的危险因素。

要点

  • 化疗和(或)HSCT后大部分患儿丧失乙肝保护性抗体,治疗前阳性者74.3%转阴。
  • 再接种3剂乙肝疫苗后97.9%患儿HBsAb转阳,无严重不良反应。
  • HSCT和治疗前HBsAb低于328.2 U/L是HBsAb转阴的危险因素。

核心结论

  • 化疗和(或)HSCT治疗后大部分患儿完全丧失对乙肝的保护性体液免疫。
  • 乙肝疫苗再接种可取得较高转阳率且安全性良好,值得在此类人群中推广。

研究设计与样本

  • 前瞻性研究,纳入2017年3月至2019年7月上海儿童医学中心疫苗接种门诊完成化疗和(或)HSCT的患儿239例。
  • 按基础疾病分为白血病组85例、淋巴瘤组30例、实体瘤组49例、非恶性血液病组75例。
  • 按治疗方式分为化疗组126例、HSCT组89例、化疗+HSCT组24例。

主要发现

  • 治疗前179例(74.9%)HBsAb阳性,60例(25.1%)阴性。
  • 治疗前HBsAb阳性的179例中,治疗后133例(74.3%)转为阴性。
  • 单因素分析显示不同基础疾病(χ²=10.211,P=0.015)、治疗方式(χ²=14.899,P<0.01)和治疗前HBsAb水平(χ²=32.117,P<0.01)组间HBsAb转阴率差异有统计学意义。
  • 多因素Logistic回归显示HSCT(以化疗组为参照,OR=2.999,95%CI 1.276~7.050,P=0.012)和治疗前HBsAb低于328.2 U/L(以治疗前HBsAb≥328.2 U/L为参照,OR=6.397,95%CI 3.159~12.954,P<0.01)是HBsAb转阴的危险因素。
  • 48例HBsAb阴性且接受乙肝疫苗再接种的患儿中,47例(97.9%)HBsAb转为阳性,无严重不良反应发生。

关键数值与推荐

  • HBsAb滴度<10 U/L定义为阴性,≥10 U/L定义为阳性。
  • 对部分HBsAb阴性患儿进行3剂乙肝疫苗再接种,完成接种后1个月测定血清HBsAb水平。
  • 治疗前HBsAb低于328.2 U/L是HBsAb转阴的危险因素(OR=6.397,95%CI 3.159~12.954,P<0.01)。

临床怎么用

  • 对完成化疗和(或)HSCT的患儿应监测HBsAb水平,识别乙肝保护性抗体丧失者。
  • 对HBsAb阴性患儿可考虑3剂乙肝疫苗再接种,再接种后转阳率高且安全性好。
  • HSCT治疗或治疗前HBsAb低于328.2 U/L的患儿HBsAb转阴风险更高,应重点关注。

局限性

  • 再接种分析仅纳入48例HBsAb阴性患儿,样本量有限。
  • 研究为单中心前瞻性研究,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess the anti-hepatitis B surface antibody (HBsAb) titers in children after completion of chemotherapy and (or) hematopoietic stem cell transplantation (HSCT), evaluate the efficacy and safety of the current hepatitis B re-vaccination schedule. Methods: A total of 239 children who completed their chemotherapy and (or) HSCT and visited the vaccination clinic of Shanghai Children's Medical Center from March 2017 to July 2019 were enrolled in this study. According to the previous diseases, patients were divided into leukemia group (85 cases), lymphoma group (30 cases), solid tumor group (49 cases) and non-malignant hematological disease group (75 cases). According to the treatment of previous diseases, the patients were divided into chemotherapy group (126 cases), HSCT group (89 cases) and chemotherapy plus HSCT group (24 cases). HBsAb titers were assessed both at the time of diagnosis and after completion of treatment and some children who were HBsAb seronegative were re-vaccinated with 3 doses of hepatitis B vaccine, the vaccine-related adverse reactions were monitored. HBsAb titers were measured again one month after the completion of inoculation. HBsAb titers were defined as negative at levels <10 U/L and positive at ≥ 10 U/L. Chi-square test or Fisher exact test was used to compare the difference of negative conversion rate of hepatitis B antibody between groups, and Logistic regression was used to explore the risk factors of hepatitis B antibody negative conversion. Results: Among 239 patients, there were 143 males and 96 females. At the time of diagnosis, 179 patients (74.9%) were HBsAb seropositive and 60 patients (25.1%) were HBsAb seronegative. After completion of chemotherapy and (or) HSCT, 133 of 179 children with HBsAb seropositive (74.3%) at diagnosis became HBsAb seronegative. Univariate analysis showed significant differences at the negative conversion rates of HBsAb between different disease groups (χ²=10.211,P=0.015), different treatments groups (χ²=14.899,P<0.01) and different HBsAb titers groups before treatment (χ²=32.117,P<0.01). Logistic regression showed that HSCT (chemotherapy group as the reference, odds ratio (OR)=2.999, 95% confidence interval (CI) 1.276-7.050,P=0.012) and HBsAb titers<328.2 U/L before treatment (HBsAb titers≥328.2 U/L group as the reference, OR=6.397, 95% CI3.159-12.954,P<0.01) were risk factors for negative conversion of HBsAb. Among 48 patients whose HBsAb was seronegative after completion of chemotherapy and (or) HSCT and re-vaccinated with hepatitis B vaccine, 47 (97.9%) cases became HBsAb seropositivie. No serious adverse effects or complications were reported among these patients. Conclusions: After completion of chemotherapy and (or) HSCT, most children completely lose their protective humoral immunity against hepatitis B. Hepatitis B re-vaccination schedule can be efficiently and safely applied in those patients. 目的: 评估接受化疗和(或)造血干细胞移植(HSCT)后患儿血清乙型病毒性肝炎(乙肝)表面抗体(HBsAb)水平及乙肝疫苗再接种的有效性和安全性。 方法: 前瞻性研究。以2017年3月至2019年7月于上海儿童医学中心疫苗接种门诊就诊的完成化疗和(或)HSCT后患儿239例为研究对象,根据基础疾病分为白血病组(85例)、淋巴瘤组(30例)、实体瘤组(49例)和非恶性血液病组(75例)。根据基础疾病治疗方式分为化疗组(126例)、HSCT组(89例)和化疗+HSCT组(24例)。测定其治疗前后患儿血清HBsAb水平;对部分HBsAb阴性患儿进行3剂乙肝疫苗再接种,监测接种后疫苗相关不良反应,并于完成接种后1个月测定血清HBsAb水平。HBsAb滴度<10 U/L为阴性,≥10 U/L为阳性。采用χ²检验或Fisher精确检验比较组间HBsAb转阴率差异,并通过Logistic回归探讨HBsAb转阴的危险因素。 结果: 入组239例患儿中男143例、女96例。化疗和(或)HSCT前,179例(74.9%)HBsAb阳性,60例(25.1%)HBsAb阴性;化疗和(或)HSCT结束后,具有乙肝保护性抗体的179例患儿中,133例(74.3%)HBsAb转为阴性;单因素分析显示不同基础疾病(χ²=10.211,P=0.015)、治疗方式(χ²=14.899,P<0.01)和治疗前HBsAb水平(χ²=32.117,P<0.01)组患儿治疗后HBsAb转阴率差异有统计学意义。多因素Logistic回归分析发现,接受HSCT治疗[以化疗组为参照,比值比(OR)= 2.999,95% 可信区间(CI)1.276~7.050,P=0.012]和治疗前HBsAb低于328.2 U/L(以治疗前HBsAb≥328.2 U/L为参照,OR=6.397,95%CI3.159~12.954,P<0.01)是HBsAb转阴的危险因素。48例血清HBsAb阴性且接受乙肝疫苗再接种患儿中,47例(97.9%)HBsAb滴度转为阳性,且无严重不良反应发生。 结论: 化疗和(或)HSCT治疗后,大部分患儿完全丧失对乙肝的保护性体液免疫。对其进行再接种可取得较高的转阳率,且具有较好的安全性,值得在此类人群中推广。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yuan Q, Zhou F, Zhang H, et al. [Efficacy and safety of hepatitis B re-vaccination in children after completion of chemotherapy and(or) hematopoietic stem cell transplantation]. Zhonghua Er Ke Za Zhi. 2020. PMID: 32987458. doi:10.3760/cma.j.cn112140-20200307-00195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。